These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29885746)

  • 1. The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis.
    Okada M; Suemori K; Takagi D; Teraoka M; Yamada H; Ishizaki J; Matsumoto T; Hasegawa H; Hato N
    Auris Nasus Larynx; 2019 Feb; 46(1):38-42. PubMed ID: 29885746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between ear involvement and clinical features and prognosis in ANCA-associated vasculitis.
    Hosokawa Y; Okada M; Suemori K; Hamaguchi N; Miyoshi KI; Takagi T; Teraoka M; Yamada H; Ishizaki J; Matsumoto T; Hato N
    Auris Nasus Larynx; 2021 Oct; 48(5):885-889. PubMed ID: 33589280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Kunimoto Y; Matsui T; Sakaguchi H; Okada M; Watanabe T; Inagaki A; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Mod Rheumatol; 2017 Jan; 27(1):87-94. PubMed ID: 27166750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
    Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hearing prognosis of otitis media with ANCA-associated vasculitis.
    Iwata S; Okada M; Suemori K; Teraoka M; Yamada H; Ishizaki J; Matsumoto T; Hato N
    Auris Nasus Larynx; 2021 Jun; 48(3):377-382. PubMed ID: 32951931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intractable otitis media - Pathogenesis and treatment of Eosinophilic otitis media (EOM) and otitis media with Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV).
    Yoshida N
    Auris Nasus Larynx; 2023 Apr; 50(2):171-179. PubMed ID: 35934599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Localized and Systemic Otitis Media With ANCA-Associated Vasculitis.
    Okada M; Suemori K; Takagi D; Teraoka M; Yamada H; Hato N
    Otol Neurotol; 2017 Dec; 38(10):e506-e510. PubMed ID: 28885482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Okada M; Kunimoto Y; Watanabe T; Inagaki A; Yoshida T; Imaizumi M; Nakamura T; Matsunobu T; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Auris Nasus Larynx; 2021 Feb; 48(1):2-14. PubMed ID: 32768313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Otolaryngologic manifestations of antineutrophil cytoplasmic antibody-associated vasculitis.
    Nakamaru Y; Takagi D; Oridate N; Homma A; Fukuda S
    Otolaryngol Head Neck Surg; 2012 Jan; 146(1):119-21. PubMed ID: 21987646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
    Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
    Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.